MOUD Naltrexone LA denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for moud naltrexone la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on MOUD Naltrexone LA
## Why Cigna Applies Quantity Limits to Long-Acting Naltrexone — and How to Appeal
Quantity-limit (QL) denials mean Cigna will cover the drug up to a defined frequency or supply, and your prescription as written exceeds that limit. For a once-monthly injectable like long-acting naltrexone, QL denials most often arise from billing or dosing-frequency discrepancies, or from a plan that has set limits inconsistent with standard clinical practice. These denials are appealable.
## Why Quantity-Limit Denials Are Challengeable
Cigna's quantity limits must have a clinical basis. If the limit is more restrictive than what the FDA-approved prescribing label specifies as the standard dosing interval, that is grounds for a quantity-limit exception. Additionally, federal parity law prohibits applying quantity restrictions to substance use disorder medications that are more stringent than restrictions applied to analogous chronic-condition medications. Your prescriber should confirm the prescribed frequency is consistent with the FDA label and document the clinical rationale.
## Your Federal Appeal Rights
- Quantity-limit exception / internal appeal (ERISA §503 / ACA §2719): Request a formal exception and file a simultaneous internal appeal. You have the right to a full-and-fair review with access to the criteria used.
- External review (ACA §2719): If the internal process fails, request IRO review within approximately four months of the denial. Expedited review is available when treatment delay creates serious clinical risk.
## Appeal Timeline
1. Request Cigna's quantity-limit criteria for this drug in writing on the denial date. 2. Confirm with the prescriber that the prescribed frequency aligns with the FDA-approved label dosing interval. 3. Submit the internal appeal with the documentation below. 4. If denied, file external IRO review within the statutory window.
## Documentation to Gather
- FDA label dosing interval: A reference to the FDA-approved prescribing information (publicly available at DailyMed) confirming the standard dosing frequency — do not state specific numbers here; let the label speak for itself.
- Prescriber letter: States that the prescribed quantity matches the FDA-approved dosing schedule and the clinical reason for that frequency.
- Parity comparison: A written statement identifying whether Cigna applies comparable quantity limits to other once-monthly injectable medications for non-behavioral chronic conditions.
- Chart documentation: Notes confirming the patient is currently receiving and benefiting from treatment, and that a quantity reduction would disrupt continuity of care.
## Criteria-Mapping Structure
Request Cigna's quantity-limit exception criteria in writing. Map each requirement to a specific chart fact or prescriber attestation. Submit as a labelled exhibit. If the limit appears to be a billing configuration error, ask Cigna's pharmacy team to verify the NDC and billing code before proceeding to full appeal.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →